Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

The U.S. Department of Health and Human Services or HHS said it will provide approximately $590 million to Moderna (MRNA) to ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Given the uncertainty regarding its top-line growth, we would advise short-term investors to steer clear of MRNA stock.

“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...

Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...

Demand for its COVID vaccine has been waning after the pandemic, while adoption of its RSV shot - its second approved product ...

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

BioNTech and Moderna COVID-19 vaccines use mRNA technology in their vaccines to protect us from the spread of the disease.